Posted by Michael Wonder on 12 Jul 2018
Cancer drug for children recommended after becoming cost effective for NHS patients
12 July 2018 - Around 60% of children with high-risk neuroblastoma could be treated with dinutuximab beta.
Seriously ill children battling high-risk neuroblastoma - a rare type of cancer that mainly affects children and young people – are to be offered a drug which has potential to extend their lives.
A NICE appraisal committee has recommended dinutuximab beta in final draft technology appraisal guidance published today.
